Price
614.05
-1.38%52W Range
Market Cap
₹1,229.93 Cr
Traded: ₹1.48 Cr (0.12%) 0.0x
Free Float: ₹513.25 Cr (0.29% of FF traded)
Volume · 60D trend
24.03 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | +16.0% | +15.0% | +14.0% | -- | -- | Decelerating |
| Return | +10.0% | +14.0% | +10.0% | +14.0% | -- | Stable |
| Profit | +14.0% | +7.0% | +7.0% | -- | +12.0% | Stable |
| Sales | +5.0% | +10.0% | +10.0% | -- | +10.0% | Stable |
Quarterly Results
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 177 | 187 | 166 | 163 | 154 | 168 | 147 | 161 | 147 | 142 | 146 | 156 | 136 | 112 | 134 | 141 |
| Expenses | 150 | 162 | 143 | 138 | 130 | 141 | 123 | 133 | 125 | 124 | 117 | 125 | 115 | 96 | 107 | 112 |
| Operating Profit | 27 | 25 | 24 | 25 | 24 | 27 | 24 | 28 | 23 | 18 | 30 | 31 | 21 | 17 | 27 | 29 |
| OPM % | 15.0% | 13.0% | 14.0% | 16.0% | 15.0% | 16.0% | 16.0% | 18.0% | 15.0% | 13.0% | 20.0% | 20.0% | 15.0% | 15.0% | 20.0% | 21.0% |
| Other Income | 24 | -4 | 15 | 7 | 15 | -7 | 9 | 10 | 10 | 7 | 11 | 9 | 8 | 4 | 6 | 6 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Depreciation | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 |
| Profit Before Tax | 48 | 17 | 35 | 29 | 35 | 16 | 29 | 35 | 29 | 22 | 38 | 37 | 25 | 17 | 31 | 32 |
| Tax % | 24.0% | 30.0% | 18.0% | 31.0% | 22.0% | 29.0% | 28.0% | 24.0% | 20.0% | 16.0% | 26.0% | 25.0% | 25.0% | 26.0% | 29.0% | 26.0% |
| Net Profit | 36 | 12 | 29 | 20 | 28 | 12 | 21 | 26 | 24 | 19 | 28 | 28 | 19 | 13 | 22 | 24 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 18.1 | 5.8 | 14.3 | 10.0 | 13.8 | 5.8 | 10.4 | 13.2 | 11.8 | 9.3 | 14.0 | 13.8 | 9.5 | 6.3 | 10.8 | 11.8 |
| Sales Growth (YoY) | 14.9% | 11.3% | 12.9% | 1.2% | 4.8% | 18.3% | 0.7% | 3.2% | 8.1% | 26.8% | 9.0% | 10.6% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -5.3% | 12.7% | 1.8% | 5.8% | -8.3% | 14.3% | -8.7% | 9.5% | 3.5% | -2.7% | -6.4% | 14.7% | 21.4% | -16.4% | -5.0% | -- |
| OP Growth (YoY) | 12.5% | -7.4% | 0.0% | -10.7% | 4.3% | 50.0% | -20.0% | -9.7% | 9.5% | 5.9% | 11.1% | 6.9% | -- | -- | -- | -- |
| OP Growth (QoQ) | 8.0% | 4.2% | -4.0% | 4.2% | -11.1% | 12.5% | -14.3% | 21.7% | 27.8% | -40.0% | -3.2% | 47.6% | 23.5% | -37.0% | -6.9% | -- |
| Profit Growth (YoY) | -- | 0.4% | 37.7% | -24.1% | 16.9% | -37.7% | -25.9% | -4.8% | 24.5% | 48.1% | 29.8% | 16.6% | 26.6% | 14.0% | 22.8% | 3.0% |
| EPS Growth (YoY) | 30.9% | 0.5% | 37.7% | -24.1% | 16.9% | -37.8% | -25.9% | -4.7% | 24.6% | 48.2% | 29.8% | 16.6% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 211.4% | -59.3% | 43.1% | -27.8% | 139.1% | -44.3% | -21.1% | 11.3% | 27.2% | -33.6% | 1.4% | 45.4% | 51.4% | -41.9% | -8.9% | -- |
| OP Margin | 15.3% | 13.4% | 14.5% | 15.3% | 15.6% | 16.1% | 16.3% | 17.4% | 15.7% | 12.7% | 20.6% | 19.9% | 15.4% | 15.2% | 20.1% | 20.6% |
| Net Margin | 20.3% | 6.4% | 17.5% | 12.3% | 18.2% | 7.1% | 14.3% | 16.1% | 16.3% | 13.4% | 19.2% | 17.9% | 14.0% | 11.6% | 16.4% | 17.0% |
| Material Cost % | -- | 47.6% | 45.7% | 47.0% | 45.0% | 47.7% | 46.8% | 44.9% | 47.7% | 51.6% | 45.8% | 47.3% | 47.1% | 43.1% | 47.8% | 48.1% |
| Employee Cost % | -- | 17.3% | 18.4% | 18.6% | 20.6% | 16.4% | 19.1% | 17.3% | 19.7% | 17.6% | 18.1% | 16.0% | 19.5% | 20.5% | 17.7% | 16.4% |
| P/S | 1.77 | 1.77 | 1.92 | 2.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 12.75 | 13.51 | 14.26 | 15.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 1.62 | 1.57 | 1.75 | 1.77 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50We enclosed herewith the copies of newspaper intimation with respect to the unaudited (standalone & Consolidated) Financial Results of the Company for the Quarter Ended 30 June, 2026.
Un-Audited Financial Results For Quarter Ended on 30 June, 2026.
Un-Audited Financial Results of the Company For the Quarter Ended June 30, 2026.
Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve Lincoln Pharmaceuticals ....
Pursuant to provision of Regulation 74(5) of SEBI (Depository and Participants) Regulation, 2018, we hereby submit the confirmation certificate received from MUFG Intime India Private Limited, ....
Intimation of Trading Window Closure for the Quarter ended June 30, 2026.
We enclosed herewith the copies of published newspaper advertisement with respect to Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Year ended March 31, 2026.
Outcome of Board Meeting for Audited Financial Results for the Quarter and Year Ended 31st March, 2026.
Recommended a Final Dividend of Rs. 1.80/- (i.e 18%) per equity share of face value Rs. 10/- each for the financial year ended March 31, 2026 subject to approval of the members at the ensuing ....
Audited Financial Results for the Quarter and Year ended March 31, 2026.
Meeting of the Board of Directors is scheduled to be held on May 28, 2026 to consider and approve Audited Financial Results of the Company and recommendation of Dividend on equity shares ....
Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve Audited (standalone ....
Annual Secretarial Compliance Report for the financial year ended March 31, 2026.
Copies of Newspaper Advertisement as required under Rule 6 of IEPF Authority (Accounting, Audit, Transfer and Refund)Rules, 2016 and amendments thereof.
<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Pursuant to Provision of Regulation 74(5) of SEBI (Depository and Participants) Regulation, 2018, We hereby submit the confirmation Certificate received from MUFG Intime India Private Limited, ....
Intimation of Closure of Trading Window.
Pursuant to Regulation of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 we attach herewith transcript of conference call held on February 18, 2026. A copy of ....
We wish to inform you that the Company participated in investor conference- Call Conference on February 18, 2026. No Unpublished Price Sensitive Information (UPSI) was shared / discussed ....
Intimation of Schedule of earnings conference call to discuss the unaudited Financial Results of the Company for the quarter and nine months ended 31st December 2025.
Newspaper Advertisement with respect to unaudited financial results (Standalone & Consolidated) for the quarter and nine months ended on December 31, 2025.
Unaudited Financial Results of the Company for the Quarter and Nine Months ended on 31.12.2025.
Outcome of the meeting held today
Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 ,inter alia, to consider and approve unaudited Financial ....
Update on Credit Rating.
Pursuant to provision of Regulation 74(5) of SEBI (Depository and Participants) Regulation, 2018, we hereby submit the confirmation certificate received from MUFG Intime India Private Limited, ....
Intimation of Closure of Trading Window
Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 ,inter alia, to consider and approve Standalone and Consolidated ....
With reference to the above, please find enclosed herewith the Minutes of 31st Annual General Meeting of the Company held at 11:00 A.M on Tuesday, the 30th September, 2025 through Video ....
Newspaper Advertisement regarding the opening of special window for re-lodgement of transfer requests of physical shares.
Certificate from RTA for the Quarter ended September 30, 2025 under Regulation 74(5) of SEBI (DP) Regulations, 2018.
Submission of Scrutinizers'' Report of 31st AGM of the Company.
Submission of E-Voting Results of 31st AGM along with the Scrutinizer Report as per Regulation 44 of SEBI (LODR) Regulation, 2015.
Submission of Proceedings of the 31st Annual General Meeting of the Company held today.
Intimation of Closure of Trading Window.
Newspaper Publication for Notice of 31st Annual General Meeting.
Intimation regarding dispatch of physical communication to the Shareholders who have not registered their email address.
Pursuant to Regulation 34(1) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the SEBI Listing Regulations"), we are submitting ....
31st Annual General Meeting ("AGM") of the Members of the Company will be held on Tuesday, 30th September, 2025 at 11:00 A.M (IST) through Video Conferencing ("VC")/Other Audio-Visual Means ....
We wish to inform you that Mr. Raja Karunanidhi Nagarajan has been appointed as "Senior General Manager- Research & Development" (Senior Management Personnel) of the Company w.e.f 29-08-2025.
The Intimation of Book Closure and Record Date is as enclosed.
Pursuant to the Regulation 42 of SEBI (LODR) Regulations, 2015 , we would like to inform you that the 31st Annual General Meeting of the Company is scheduled to be held on Tuesday, September ....
Newspaper Advertisement regarding the 31st Annual General Meeting of the Company to be held on Tuesday, September 30, 2025.
We enclosed herewith the copies of newspaper intimation with respect to the Unaudited (Standalone & Consolidated) Financial Results of the Company for the Quarter ended on 30.06.2025.
Appointment of Secretarial Auditors.
Re-appointment of Managing Director and Whole-time Directors of the Company
UN AUDITED FINANCIAL RESULTS FOR QUARTER ENDED ON 30-JUNE-2025.
UN-AUDITED FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER ENDED ON 30-JUNE-2025
Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2025 ,inter alia, to consider and approve the Unaudited Standalone ....
Annual Reports
15Credit Ratings
6Concalls
30Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025May 2025
31 May 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Jun 2024
30 Jun 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Oct 2023
31 Oct 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Jul 2022
31 Jul 2022Apr 2021
30 Apr 2021Jan 2021
31 Jan 2021Oct 2020
31 Oct 2020Jul 2020
31 Jul 2020Apr 2020
30 Apr 2020Jan 2020
31 Jan 2020Oct 2019
31 Oct 2019Jul 2019
31 Jul 2019Apr 2019
30 Apr 2019Jan 2019
31 Jan 2019Oct 2018
31 Oct 2018Jul 2018
31 Jul 2018Apr 2018
30 Apr 2018Jan 2018
31 Jan 2018Oct 2017
31 Oct 2017Jul 2017
31 Jul 2017Aug 2016
31 Aug 2016Held by ETFs
1 ETFs hold LINCOLN · sorted by weight
Held by Mutual Funds
1 schemes hold LINCOLN · sorted by weight